Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer

NCT00322517 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00322517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2006
Completion date
July 31, 2009
Enrollment
90 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms